Core Viewpoint - Zoetis Inc. is expected to report stable earnings and revenue for its fourth quarter, with analysts projecting earnings per share to remain at $1.4 and revenue to increase slightly to $2.36 billion from $2.32 billion in the previous year [1][2]. Financial Performance - The anticipated earnings per share for Zoetis in the fourth quarter is $1.4, consistent with the same period last year [1]. - The consensus estimate for quarterly revenue is $2.36 billion, reflecting a growth from $2.32 billion reported in the previous year [1]. Recent Developments - On December 16, Zoetis announced the pricing of a $1.75 billion convertible senior notes offering, indicating a significant capital-raising effort [1]. - Shares of Zoetis rose by 0.4%, closing at $128.67 on Wednesday, suggesting a positive market response [2].

Core Insights - Elanco Animal Health Incorporated (NYSE:ELAN) is recognized as a promising healthcare stock priced under $50, with recent positive adjustments in its stock ratings and price targets from multiple financial institutions [1][2]. Group 1: Rating Updates - BofA raised its price target for Elanco to $28 from $25 on January 30, maintaining a Buy rating, citing stronger operational results [1]. - UBS increased its price target to $30 from $27 on January 29, also reaffirming a Buy rating [1]. - Piper Sandler upgraded Elanco to Overweight from Neutral on January 22, raising the price target to $30 from $24, indicating positive developments observed at the VMX conference [2]. Group 2: Business Overview - Elanco Animal Health is engaged in providing services and products aimed at preventing and treating diseases in both pets and farm animals, with a diverse portfolio that includes species such as cats, dogs, cattle, swine, poultry, and sheep [3].

Core Insights - The article discusses the current state of healthcare stocks, particularly focusing on the impact of proposed changes to Medicare Advantage payments, which are expected to be minimal, leading to negative implications for major insurers [2][3]. Industry Overview - The healthcare sector has been described as "precarious" for investment over the past couple of years, with the recent Medicare Advantage proposal causing a shock to the system [3][4]. - Investors had anticipated a turnaround year, but the current outlook suggests a period where earnings may not grow as expected, indicating a challenging environment for healthcare investments [4]. Company Highlights - **Genmab A/S (NASDAQ:GMAB)**: - Reported worldwide net trade sales of DARZALEX at $14.351 billion for 2025, with $8.266 billion from the U.S. and $6.085 billion from the rest of the world [10]. - Analysts have adjusted price targets, with H.C. Wainwright setting it at $39 and BofA at $38.50, both maintaining a Buy rating, citing a "catalyst-rich" fiscal 2026 [11]. - The company focuses on developing human antibody therapeutics for cancer and other diseases, with a strong product pipeline [12]. - **Elanco Animal Health Incorporated (NYSE:ELAN)**: - Received multiple rating updates, with BofA raising the price target to $28 and UBS to $30, both maintaining Buy ratings due to stronger operational results [13][14]. - Piper Sandler upgraded the stock to Overweight, increasing the price target to $30, highlighting the company's progress in corporate channels [14]. - Elanco provides products and services for disease prevention and treatment in pets and farm animals, serving a diverse range of species [15].

Company Overview - Phibro Animal Health Corporation is a leading global diversified animal health and mineral nutrition company headquartered in New Jersey, providing a broad range of products for food animals including poultry, swine, beef, dairy cattle, and aquaculture [11] - The company markets nearly 770 product lines in over 80 countries to approximately 4,000 customers, also manufacturing specific ingredients for personal care, automotive, industrial chemical, and chemical catalyst industries [11] Investment Rating - Phibro Animal Health is rated 2 (Buy) on the Zacks Rank, indicating a favorable investment outlook [12] - The company has a VGM Score of A, suggesting strong overall performance across value, growth, and momentum metrics [12] Momentum and Earnings Estimates - The Momentum Style Score for Phibro Animal Health is B, with shares having increased by 25.9% over the past four weeks, indicating strong upward price momentum [12] - For fiscal 2026, one analyst has revised their earnings estimate upwards in the last 60 days, with the Zacks Consensus Estimate increasing by $0.07 to $2.83 per share [12] - The company boasts an average earnings surprise of +20.2%, reflecting its ability to exceed earnings expectations [12] Conclusion - With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, Phibro Animal Health is positioned as a strong candidate for investors' short lists [13]

Company Performance - Pelican Bay Capital Management (PBCM) reported a return of 8.5% for its Concentrated Value Strategy in Q4 2025, outperforming the Russell 1000 Value Index, which returned 3.8% [1] - For the full year, the Strategy achieved a return of 20.6%, compared to 15.9% for the Index [1] - The strong performance was attributed to AI-related stocks and commodities exposure [1] Company Addition - PBCM highlighted Zoetis Inc. (NYSE:ZTS) as a new addition to its portfolio [2] - Zoetis Inc. focuses on animal health medications, vaccines, and diagnostic products, with a market capitalization of approximately $56.165 billion [2] - As of February 4, 2026, Zoetis Inc. stock closed at $126.73 per share, with a -0.35% return in the past month and a decline of 26.07% over the past twelve months [2] Industry Insights - The global animal health market was valued at approximately $50 billion last year and is expected to grow at a rate of 5-6% per year over the next decade [3] - Growth in the animal health market is driven by trends such as pets living longer and increasing acceptance of medicines and vaccines by pet owners [3] - PBCM initiated new positions in Zoetis Inc., along with AECOM (ACM) and FactSet Research (FDS), indicating a strategic focus on high-quality companies in the animal health sector [3]

Group 1: Fund Performance - Baron Health Care Fund rose 13.10% in Q4 2025, outperforming the Russell 3000 Health Care Index which gained 11.92% and the Russell 3000 Index which gained 2.40% [1] - For the full year, the Fund returned 10.28%, compared to 14.56% and 17.15% gains for the respective indexes [1] - Strong stock selection in biotechnology contributed to the Fund's relative gains in the quarter [1] Group 2: Investment Focus - The Fund seeks to invest in businesses with secular growth opportunities, sustainable competitive edges, and strong management [1] - The healthcare sector is viewed as a strong area in the U.S. economy, offering attractive investment opportunities with positive momentum heading into 2026 [1] Group 3: Elanco Animal Health Incorporated - Elanco Animal Health has a market capitalization of $12.079 billion and closed at $24.31 per share on February 5, 2026 [2] - The stock gained 3.58% over the past month and 111.02% over the last 52 weeks [2] - Elanco operates in an attractive industry with growth drivers such as increased pet ownership and higher spending on pets [3] Group 4: Innovation and Growth Potential - Elanco's management expects innovation revenue to reach $840 million to $880 million in 2025, increasing to $1.1 billion in 2026 [3] - Key innovation products include Credelio Quattro, Zenrelia, Befrena, Bovaer, and Experior, which are expected to drive growth and gross margin expansion [3] - The innovation pipeline includes five to six additional products expected to be approved between 2026-2031, with potential peak sales of $2 billion [3] Group 5: Financial Targets - Management targets 200-350 basis points of EBITDA margin expansion from 2025-2028 [3] - The company aims for $1 billion of cumulative free cash flow from 2026-2028 to pay down debt and reduce net debt to EBITDA from 3.7-3.8 times at the end of 2025 to 2.0-2.5 times by the end of 2028 [3]

Core Viewpoint - Zoetis Inc. is a leading animal health company facing challenges in stock performance and revenue growth due to various market and company-specific factors [2][5]. Company Overview - Zoetis Inc. has a market capitalization of $56.3 billion and specializes in animal health products, including medicines, vaccines, and diagnostic solutions for both livestock and companion animals [1]. Stock Performance - Over the past 52 weeks, Zoetis shares have decreased by 27.5%, underperforming the S&P 500 Index, which gained 12.2% during the same period [2]. - Year-to-date, Zoetis shares have gained 1.3%, contrasting with a slight decline in the S&P 500 Index [2]. Competitive Analysis - Zoetis has also lagged behind the State Street Health Care Select Sector SPDR ETF, which has seen a 5.4% increase over the past year [3]. Financial Performance - In Q3 2025, Zoetis reported revenue of approximately $2.4 billion, reflecting a modest year-over-year increase of about 1% [6]. - Analysts project a 7.1% year-over-year growth in EPS for the fiscal year 2025, estimating it to reach $6.34 [6]. Analyst Ratings - The consensus rating among 17 analysts covering Zoetis is a "Moderate Buy," with eight "Strong Buy" ratings, one "Moderate Buy," and eight "Holds" [6]. - This rating configuration has become less bullish compared to three months ago, when there were 11 "Strong Buy" ratings [7]. Recent Downgrade - On January 22, 2026, Piper Sandler analyst David Westenberg downgraded Zoetis from "Overweight" to "Neutral" and reduced the price target from $190 to $135 [7].

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial Market Authority – Autorité des Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577 DateTotal number of shares representing the share capitalTotal number of voting rightsJanuary, 31 20268 390 660Gross total of voting rights : 12 704 131Net total* of voting rig ...

Phibro Animal Health Corporation Financial Results Fiscal Year 2026 Second Quarter Ended December 31, 2025 Webcast and Conference Call February 5, 2026 February 5, 2026 Webcast and Conference Call Cautionary Statement Regarding Forward-Looking Statements U.S. toll-free +1.888.330.2022 International toll +1.365.977.0051 Conference ID: 3927884 Important Information Internet Posting of Information This communication contains forward-looking statements that are subject to risks and uncertainties, including with ...

Core Viewpoint - Zomedica is focusing on its R&D strategy to support scalable growth and enhance long-term shareholder value through an upcoming investor webinar [1] Group 1 - The company is an animal health firm that provides innovative diagnostic and therapeutic devices for both equine and companion animals [1] - The next installment of the "Fourth Friday at Four" investor webinar series is scheduled for February 27, 2026, at 4:00 p.m. Eastern Time [1]